Affymax Research Institute was a drug discovery company that was acquired in March 1995, by Glaxo, now Glaxo Wellcome, one of the world's leading research-based pharmaceutical companies. The company continued to opperate as a subsidiary of Glaxo, until it went out of business in 2014. The company was a biopharmaceutical company, engaged in the development of drugs for the treatment of serious and life-threatening conditions. The company developed Hematide, which was in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. Affymax, Inc. had strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide
